We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Viral Protein Stops Inflammatory Response

By Biotechdaily staff writers
Posted on 02 Feb 2006
A viral protein has been found that inactivates the immune system's anti-inflammatory response mechanism, which shields the virus from immune attack but may be exploited as a drug to treat inflammatory diseases of the skin.

Investigators at the University of Illinois (Urbana-Champaign, USA) worked with the molluscum contagiosum virus (MCV), which causes a mild skin disease similar to chickenpox. More...
In particular they focused their attention on the product of the viral MC160 gene, which has a homologue in humans and in herpes viruses, that regulates the cellular transcription factor NF-kappaB. NF-kappaB is activated when cytokine tumor necrosis factor alpha (TNF-alpha) binds to its cognate, TNF receptor I.

Studies on the effect of the MC160 protein on T cells growing in culture showed that it significantly reduced TNF-alpha-mediated NF-kappaB activation. MC160 protein expression reduced IKK kinase activity and IKK subunit phosphorylation. This is a step common to multiple signal transduction pathways. These findings were published in the January 2006 issue of the Journal of Virology.

"Our findings regarding MC160 provide yet another example of how viruses inhibit NF-kappaB activation,” explained senior author Dr. Joanna L. Shisler, professor of microbiology at the University of Illinois. "So we are starting to get a broader feeling that there is a common mechanism, that of inhibiting NF-kappaB activity, that all viruses are trying to utilize to survive in the host. What is interesting is that MC160 appears to be doing it in a completely novel way, than any identified before, by focusing on this IKK complex. This virus makes other proteins that dampen the immune response, but MC160 seems to be an important one.”



Related Links:
University of Illinois

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
POC Immunoassay Analyzer
Procise DX
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.